Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

OncoCyte Corporation (OCX) had Revenue of $1.88M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$1.88M
Net Income	$-60.93M
Cost of Goods Sold	$1.14M
Gross Profit	$0.74M
Operating Expenses	$62.92M
Operating Income	$-61.04M
Non-Operating Income/Expense	$0.38M
Pre-Tax Income	$-60.66M
Normalized Pre-Tax Income	$-60.66M
Income after Taxes	$-60.66M
Income from Continuous Operations	$-60.66M
Consolidated Net Income/Loss	$-60.66M
Normalized Income after Taxes	$-60.66M
EBIT	$-61.04M
EBITDA	$-59.48M
Weighted-Average Shares Outstanding (Basic)	13.07M
Weighted-Average Shares Outstanding (Diluted)	13.07M
Earnings per Share (EPS) (Basic)	$-4.66
Earnings per Share (EPS) (Diluted)	$-4.66
Balance Sheet Financials
Current Assets	$11.76M
Property, Plant, and Equipment	$3.57M
Long-Term Assets	$23.32M
Total Assets	$35.08M
Current Liabilities	$7.28M
Long-Term Debt	--
Long-Term Liabilities	$40.08M
Total Liabilities	$47.35M
Common Equity	$-12.27M
Tangible Shareholders Equity	$-26.88M
Shareholders Equity	$-12.27M
Common Shares Outstanding	17.45M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-20.71M
Cash Flow from Investing Activities	$-0.51M
Cash Flow from Financial Activities	$20.43M
Beginning Cash	$11.13M
End Cash	$10.34M
Increase/Decrease in Cash	$-0.80M
Stock-Based Compensation	$1.75M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.62
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	39.34%
Operating Margin	-3245.14%
EBIT Margin	-3245.14%
EBITDA Margin	-3161.99%
Pre-Tax Profit Margin	-3225.04%
Profit Margin	-3239.02%
Free Cash Flow	$-21.23M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.05
Inventory Turnover	2.78
Receiveable Turnover	1.17
Days Sales in Receivables	313.00
Return on Equity	494.24%
Return on Tangible Equity	225.67%
Return on Assets	-172.92%
Return on Investments	494.24%
Book Value Per Share	$-0.70
Free Cash Flow per Share	$-1.62
Operating Cash Flow per Share	$-1.58

Data from Zacks Investment Research, Inc.